Salvage external beam radiotherapy of retinal capillary hemangiomas secondary to von Hippel–Lindau disease

Raja, Deepak; Benz, Matthew S.; Murray, Timothy G.; Escalona-Benz, Erika; Markoe, Arnold M.

doi:10.1016/j.ophtha.2003.04.003

Cited by 58 publications

(21 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recent review articles summarized the current knowledge about retinal, intracranial and spinal hemangiomas [1,7,9]. Capillary subtypes are rarely found and might sometimes be associated with von Hippel-Lindau disease [9].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Stereotactic Fractionated Radiotherapy for Recurrent Capillary Hemangioma of the Cavernous Sinus

Grosu¹,

Nieder

2006

Strahlenther Onkol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…Capillary subtypes are rarely found and might sometimes be associated with von Hippel-Lindau disease [9]. Their location in the cavernous sinus often leads to clinical symptoms that may require treatment.…”

Section: Discussionmentioning

confidence: 99%

Stereotactic Fractionated Radiotherapy for Recurrent Capillary Hemangioma of the Cavernous Sinus

Grosu¹,

Nieder

2006

Strahlenther Onkol

View full text Add to dashboard Cite

show abstract

“…The vascular nature of the tumors has brought interest toward using radiation as a potential treatment. Although there are no reports of secondary malignancy or malignant transformation, the total time period of follow-up is relatively short and for a limited number of patients [Pan et al, 1998;Jawahar et al, 2000;Raja et al, 2004].…”

Section: Von Hippel Lindaumentioning

confidence: 99%

Inherited disorders as a risk factor and predictor of neurodevelopmental outcome in pediatric cancer

Ullrich¹

2008

Dev Disabil Res Revs

View full text Add to dashboard Cite

Each year in the United States, an average of one to two children per 10,000 develop cancer. The etiology of most childhood cancer remains largely unknown but is likely attributable to random or induced genetic aberrations in somatic tissue. However, a subset of children develops cancer in the setting of an underlying inheritable condition involving a germline genetic mutation or chromosomal aberration. Despite overall improved survival rates for children with cancer over recent decades, many patients experience neurological and neurocognitive complications during the course of their illness and/or as late effects of treatment. Improvements in therapy, longer survival times, and improved imaging techniques have all increased both the time that patients are at risk and the ability to detect such complications. How an underlying inherited disorder influences the incidence, timing, etiology, and treatment of such sequelae has not been extensively documented, but evidence exists for an increased risk for secondary malignancies and in some cases life-threatening sensitivity/toxicity to conventionally dosed cancer treatments, thus emphasizing the need for the early recognition of such syndromes. This review outlines the major tumor- and treatment-related neurodevelopmental sequelae in pediatric cancer patients, with particular attention to children with an underlying inheritable disorder.

show abstract

“…Treatment of RCH has been accomplished by local therapy, including laser photocoagulation, cryotherapy, and radiation from brachytherapy or external beams. Current local therapies may damage normal tissue surrounding the lesions and may be ineffective for certain lesions [30].…”

Section: Surgical Therapy For Ocular Diseasementioning

confidence: 99%

“…When typical therapies are ineffective, other strategies may need to be employed. The University of Miami published a series using external beam radiotherapy to treat six eyes of five patients with RCHs that had failed first-line therapy [30]. RCHs, as with other vascular tumors, are typically quite radiosensitive.…”

Section: Surgical Therapy For Ocular Diseasementioning

confidence: 99%

Neuro-ophthalmology of von Hippel-Lindau

Fitz

Newman

2004

Curr Neurol Neurosci Rep

View full text Add to dashboard Cite

von Hippel-Lindau (VHL) disease is a multisystem inherited cancer syndrome with characteristic tumors and a known genetic basis. Patients with VHL develop, among other tumors, retinal capillary hemangiomas, central nervous system hemangioblastomas, renal clear cell carcinomas, and pheochromocytomas. Nearly all patients can be shown to have a mutation in the VHL gene, which is located on chromosome 3p25. Genetic abnormalities result in abnormal levels of pVHL, which in turn lead to the different tumors. Four distinct phenotypes of VHL disease have been identified based on the relative frequency of and propensity for the development of different VHL tumors. Aggressive screening of patients with VHL disease can prevent morbidity and mortality from these tumors. Although these tumors typically have been treated with observation or surgery, trials of newer medical therapies that target some of the cellular dysregulation caused by mutation in pVHL are ongoing. Even though these trials have not been wholly successful, they present an exciting direction for future research. This article presents a summary of new developments in VHL disease with a focus on ophthalmic and neuro-ophthalmic practice.

show abstract

Salvage external beam radiotherapy of retinal capillary hemangiomas secondary to von Hippel–Lindau disease

Cited by 58 publications

References 25 publications

Stereotactic Fractionated Radiotherapy for Recurrent Capillary Hemangioma of the Cavernous Sinus

Stereotactic Fractionated Radiotherapy for Recurrent Capillary Hemangioma of the Cavernous Sinus

Inherited disorders as a risk factor and predictor of neurodevelopmental outcome in pediatric cancer

Neuro-ophthalmology of von Hippel-Lindau

Contact Info

Product

Resources

About